ulcerative colitis

in review 5 min read Updated 2026-10-28
ulcerative colitis

Continuous mucosal inflammation from the rectum proximally. Treatment follows extent and severity: mild–moderate → 5-ASA (rectal for proctitis, rectal + oral for left-sided, oral for extensive). Moderate–severe → steroids to induce, advanced therapy to maintain; infliximab + thiopurine is the strongest anti-TNF option. Acute severe UC (≥6 bloody stools + systemic toxicity) → admit, exclude C. difficile and CMV, IV methylprednisolone 60 mg, LMWH prophylaxis, reassess day 3 → infliximab or cyclosporine rescue or colectomy. Toxic megacolon → surgery.

severity and extent

Extent (Montreal): proctitis (E1) · left-sided, to splenic flexure (E2) · extensive, beyond splenic flexure (E3). Extent decides route of 5-ASA and CRC surveillance.

Severity (Truelove–Witts):

  • mild: <4 stools/day, afebrile, normal HR, Hb >110 g/L, ESR <20
  • severe: >6 bloody stools/day + ≥1 of fever, tachycardia, anaemia or raised ESR/CRP → admit
  • moderate: in between

Treat to endoscopic improvement (Mayo 0–1), not symptoms alone. Calprotectin to track response and suspected relapse.

work-up of a flare

  • Stool C. difficile for every new diagnosis and flare (clostridioides difficile infection); enteric pathogens.
  • Colonoscopy with ileal intubation at diagnosis; biopsy normal-appearing proximal colon and rectum. Severe disease → flexible sigmoidoscopy only (perforation risk).
  • No serology (ANCA/ASCA) for diagnosis or prognosis.

mild to moderate disease

extentinductionmaintenance
proctitismesalamine suppository 1 g dailysame
left-sidedmesalamine enema ≥1 g daily + oral 5-ASA ≥2 g daily (suggested over oral alone)oral 5-ASA ≥1.5 g (Toronto: ≥2 g) ± rectal
extensiveoral 5-ASA 2–2.4 g daily (4.8 g no better for mild)oral 5-ASA ≥1.5 g
  • Rectal 5-ASA beats rectal steroids — mesalamine is first, topical steroid an add-on or if intolerant.
  • Once-daily dosing equals divided dosing → choose once daily for adherence.
  • Assess 5-ASA response at 4–8 weeks. Not responding → add budesonide MMX 9 mg or oral prednisone; don’t switch to another 5-ASA brand.
  • Steroids never maintain remission (systemic, budesonide or topical).
  • Proctitis is often undertreated with oral 5-ASA alone — it needs rectal therapy.

moderate to severe disease

Induction: budesonide MMX (moderate) or oral prednisone 40–60 mg/day → taper. Steroid-dependent, steroid-refractory or high-risk → advanced therapy.

Assess steroid response within 2 weeks and anti-TNF response at 8–12 weeks (Toronto 2015). Thiopurine or methotrexate alone don’t induce remission. Thiopurine is a reasonable maintenance after steroid induction in low-risk patients; methotrexate doesn’t maintain UC.

choosing an advanced therapy

All biologic classes, JAK inhibitors and S1P modulators are recommended. General choice (infection risk, vedolizumab vs adalimumab, loss of response, stopping 5-ASA), screening and safety → IBD advanced therapies. UC-specific points:

situationpreferred
hospitalised or severeinfliximab + thiopurine (combination strongly recommended; infliximab usual inpatient choice)
prior anti-TNF failure, wants oralupadacitinib or tofacitinib (CV risk factors → caution); ozanimod/etrasimod
  • Primary anti-TNF failure → switch to vedolizumab rather than another anti-TNF (Toronto 2015).

acute severe UC

acute severe UC admission bundle
  • stool C. difficile + enteric pathogens; CBC, CRP, albumin, electrolytes, LFTs
  • AXR — transverse colon >6 cm → toxic megacolon → urgent surgical consult
  • flexible sigmoidoscopy within 72 h (ideally 24 h) with biopsies for CMV
  • IV methylprednisolone 60 mg/day (or hydrocortisone 100 mg TID–QID)
  • LMWH prophylaxis despite rectal bleeding
  • pre-infliximab screen now (HBV, TB, HIV, VZV) → IBD advanced therapies
  • stop NSAIDs, opioids, anticholinergics, antidiarrhoeals
  • correct K⁺ and Mg²⁺ (and before cyclosporine)
  • no routine antibiotics; no TPN for bowel rest
  • colorectal surgery consult on admission
  • daily stool count, blood, abdominal exam, CRP
  • day 3: >8 stools, or 3–8 stools + CRP >45 → rescue therapy or colectomy

Day-3 decision (Oxford criteria above → ~85% colectomy without rescue):

  • Infliximab 5 mg/kg; consider 10 mg/kg if albumin <25 g/L (protein-losing colon clears drug); accelerated induction lacks long-term benefit. Don’t give sequential cyclosporine → infliximab rescue. Continue infliximab as maintenance if it works.
  • Cyclosporine 2 mg/kg/day IV → oral; bridge to thiopurine or vedolizumab maintenance. Choose by local experience, prior thiopurine failure (cyclosporine needs a thiopurine to bridge to), and low albumin and cholesterol (cyclosporine neurotoxicity).
  • No response to rescue in 5–7 days, or deterioration at any time → colectomy. Infliximab or cyclosporine exposure doesn’t increase surgical complications — don’t delay surgery for it.
  • JAK inhibitors as rescue: insufficient data for routine use.

CMV colitis — up to a third of steroid-refractory ASUC. Diagnose by biopsy immunohistochemistry or tissue PCR (serum PCR poor). Treat with ganciclovir; don’t hold colectomy while treating.

toxic megacolon

Perforation or massive haemorrhage → colectomy. Toxic megacolon (transverse colon >6 cm + systemic toxicity) → urgent surgical consult; usually colectomy (ACG lists it as a surgical indication).

long-term care

  • CRC surveillance colonoscopy from 8 years after diagnosis in colitis beyond the rectum; PSC → from diagnosis, every 1–2 years. Controlling inflammation lowers dysplasia risk. A first-degree relative with CRC adds risk — family-history screening rules → cancer screening — Canadian guidelines.
  • PSC: proximal-predominant colitis with relative rectal sparing; cholestatic LFTs → MRCP (primary biliary and sclerosing cholangitis).
  • Smoking is protective in UC, but cessation is still advised.
  • Bone health, anaemia, vaccines and pre-therapy screening → IBD advanced therapies.
  • Screen for anxiety and depression.
  • Distinguishing UC from Crohn’s → Crohn’s disease.

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

Suggest a correction ulcerative colitis